Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs)

Giles, 2005, Topoisomerase enzymes as therapeutic targets for cancer chemotherapy, Med. Chem., 1, 383, 10.2174/1573406054368738 Byl, 2001, DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action, Biochemistry, 40, 712, 10.1021/bi0021838 Chikamori, 2010, DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy, Curr. Cancer Drug Targets, 10, 758, 10.2174/156800910793605785 Hurley, 2002, DNA and its associated processes as targets for cancer therapy, Nat. Rev. Cancer, 2, 188, 10.1038/nrc749 Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011 Fu, 2008, Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression, Nat. Cell. Biol., 10, 1076, 10.1038/ncb1767 Gotink, 2010, Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?, Angiogenesis, 13, 1, 10.1007/s10456-009-9160-6 Drevs, 2003, Receptor tyrosine kinases: the main targets for new anticancer therapy, Curr. Drug Targets, 4, 113, 10.2174/1389450033346885 Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483 Tsanakopoulou, 2008, Indeno[1,2-d]pyrido[1,2-a]pyrimidines: a new class of receptor tyrosine kinase inhibitors, Chemmedchem, 3, 429, 10.1002/cmdc.200700306 Jung, 2010, Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo, Carcinogenesis, 31, 911, 10.1093/carcin/bgp221 Presta, 2005, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine Growth Factor Rev., 16, 159, 10.1016/j.cytogfr.2005.01.004 Chow, 2007, Sunitinib: from rational design to clinical efficacy, J. Clin. Oncol., 25, 884, 10.1200/JCO.2006.06.3602 Gangjee, 2010, Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents, J. Med. Chem., 53, 1563, 10.1021/jm9011142 Tao, 2007, Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors, J. Med. Chem., 50, 1514, 10.1021/jm061247v Cai, 2008, J. Med. Chem., 51, 1976, 10.1021/jm7013309 Ma, 2008, Combination of antiangiogenesis with chemotherapy for more effective cancer treatment, Mol. Cancer Ther., 7, 3670, 10.1158/1535-7163.MCT-08-0715 Borisy, 2003, Systematic discovery of multicomponent therapeutics, Proc. Natl. Acad. Sci. U. S. A, 100, 7977, 10.1073/pnas.1337088100 Braña, 2001, Naphthalimides as anticancer agents: synthesis and biological activity, Curr. Med. Chem. – Anti-cancer Agents, 1, 237, 10.2174/1568011013354624 Ingrassia, 2009, Naphthalimides and azonafides as promising anti-cancer agents, Curr. Med. Chem., 16, 1192, 10.2174/092986709787846659 Mijatovic, 2008, UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers, Neoplasia, 10, 573, 10.1593/neo.08290 Kuhn, 2007, Phase I/II dose-escalation trial of amonafide for treatment of advanced solid tumors: genotyping to optimize dose based on polymorphic metabolism, J. Clin. Oncol., 25, 2503, 10.1200/jco.2007.25.18_suppl.2503 Wu, 2009, Novel naphthalimide derivatives as potential apoptosis-inducing agents: design, synthesis and biological evaluation, Eur. J. Med. Chem., 44, 4674, 10.1016/j.ejmech.2009.07.011 Lv, 2009, Overview of naphthalimide analogs as anticancer agents, Curr. Med. Chem., 16, 4797, 10.2174/092986709789909576 Chen, 2010, A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis, J. Med. Chem., 53, 2589, 10.1021/jm100025u Iranpoor, 2002, Triphenylphosphine/2,3-dichloro-5,6-dicyanobenzoquinone as a new, selective and neutral system for the facile conversion of alcohols, thiols and selenols to alkyl halides in the presence of halide ions, Tetrahedron, 58, 8689, 10.1016/S0040-4020(02)01089-X Brana, 2001, Intercalators as anticancer drugs, Curr. Pharm. Des., 7, 1745, 10.2174/1381612013397113 Zhu, 2007, R16, a novel amonafide analogue, induces apoptosis and G(2)-M arrest via poisoning topoisomerase II, Mol. Cancer Ther., 6, 484, 10.1158/1535-7163.MCT-06-0584 Tanabe, 1991, Inhibition of topoisomerase-II by antitumor agents bis(2,6-dioxopiperazine) derivatives, Cancer Res., 51, 4903 Tian, 2009, Conjugation of substituted naphthalimides to polyamines as cytotoxic agents targeting the Akt/mTOR signal pathway, Org. Biomol. Chem., 7, 4651, 10.1039/b912685f Xie, 2010, NNINspm, naphthalimide-polyamine conjugate, induces hepatoma HepG2 cell apoptosis via PI3K/Akt pathways, Chin. Pharm. Bull., 26, 169 Marx, 2003, Angiogenesis: a boost for tumor starvation, Science, 301, 452, 10.1126/science.301.5632.452 Powers, 2000, Fibroblast growth factors, their receptors and signaling, Endocr. Relat. Cancer, 7, 165, 10.1677/erc.0.0070165 Tan, 2013, Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation, Eur. J. Med. Chem., 62, 130, 10.1016/j.ejmech.2012.12.039 Alsenz, 2007, High throughput solubility measurement in drug discovery and development, Adv. Drug Delivery Rev., 59, 546, 10.1016/j.addr.2007.05.007 Tong, 2011, Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors, Acta Pharmacol Sin, 32, 930, 10.1038/aps.2011.23 Osusky, 2004, The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels, Angiogenesis, 7, 225, 10.1007/s10456-004-3149-y Kruczynski, 2006, Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development, Eur. J. Cancer, 42, 2821, 10.1016/j.ejca.2006.06.019 Xie, 2011, AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo, PLoS One, 6, e21487, 10.1371/journal.pone.0021487